Thursday, May 17, 2007 12:35:28 AM
>>> 09:32 am Cougar Biotechnology: Cowen & Co initiates Outperform. Cowen initiates CGRB with an Outperform saying the lead product CB7630 is supported by compelling Phase I and Phase II data and has the potential to be a blockbuster product in the large and dynamic prostate cancer market. The firm expects Phase III trials in chemotherapy-refractory patients to begin in H1:08. Additional product candidates CB3304 and CB1089 round out Cougar's pipeline. The firm believes CGRB shares will significantly outperform the market as investors gain greater comfort and appreciation for CB7630's $500 mln+ sales potential. <<<
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM
HealthLynked Corp Announces First Quarter 2024 Results: Achieves 8% Revenue Growth Over Last Quarter • HLYK • May 16, 2024 8:00 AM